Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter




Read in Swedish

Report from Extraordinary General Meeting of Vitrolife AB (publ)

16:00 / 20 October 2021 Vitrolife Press release

At Vitrolife's Extraordinary General Meeting today, the following, amongst other things, was decided:
  • Non-cash consideration issue in accordance with the board's proposal with the purpose of financing the acquisition of Igenomix.

  • Vesa Koskinen, partner at EQT, is elected new board member and the board is thus expanded with one member. The board remuneration is increased because of the additional member. The decision is conditional on the non-cash issue being carried out.

Gothenburg, October 20, 2021
The Board


Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:

Show as PDF

Show original from Cision


This information was distributed by Cision